



STOCK STATUS REPORT AS AT 1ST MAY 2012

For actual of dates of data collection, refer to the detail for each commodity

Introduction

The purpose of this report is to inform Ministry of Health officials especially program managers and all stakeholders of the stock levels in the country in order for appropriate logistics decisions to be made and implemented. This report highlights challenges, bottlenecks and recommends potential solutions to mitigate stock outs and expiries of ARVs & HIV test kits, ACTs, Anti-TB medicines, Reproductive Health items, selected Laboratory commodities and selected medicines for opportunistic infections.

It can be used to:

- Identify challenges and recommendations to avert supply interruptions
- Encourage preparation and sharing of joint supply plans with stakeholders
- Identify strategies for regularly reviewing supply plans for all the commodities
- Encourage donors to honor their commitments in terms of quantities of products expected, timeliness of deliveries and flexibility.

Summaries of the Central Inventory Level Stock Status	Risk of stock out	Justification
---	-------------------	---------------

ACTs

Stock levels for the packs of 24, 12 and 18 tablets are all below the recommended minimum stock level with all products having a poor pipeline in the next two months. Joint Medical Store (JMS) stock level is more stable compared to that at the National Medical Stores (NMS). There is need to place orders for the products and expedite Quality Chemicals Industries Ltd deliveries to NMS if the country is to avert looming stock outs.

Other antimalarials

Artesunate injection is not yet available in stock at both JMS and NMS. The procurement of Artesunate has been put on hold following a review of the planned policy shift for the management of complicated malaria. Procurement will be initiated after this policy direction is retabled at both HPAC and MoH management for further discussion.


Quinine injection in nearly out of stock. NMS continues to call off stock from their existing framework contract, but will need to strongly consider raising the re-order level for this product. At the same time there is need to plan for the phase-out and overall coordination of the supply side to prevent stock-piles at both central and facility levels.

Sulphadoxine/Pyrimethamine (SP) has stocked out at both NMS and JMS. There is need to urgently place an order from the framework contract.

High

Stocked out practically

All bands of ACTs as well as Sulphadoxine + Pyrimethamine are below minimum stock level recommended for central level warehousing facilities. Shipments must be immediately planned and fast-tracked



ARVs for adults

A) - First Line Products

The stock levels of EFV, AZT/3TC/NVP and AZT/3TC adult formulations at NMS have all fallen below the minimum stock level of six months although pipeline is appearing relatively fine. JMS has virtually stocked out of these products. Global Fund procurements to replenish JMS of these products have been confirmed for July/August 2012. Stock levels for NVP and TDF/3TC are below minimum posing a risk of stock insufficiencies. Procurements are ongoing for supplies from Quality Chemicals and Global Fund. JMS has low stock levels for most products.


There are planned procurements from Global Fund Round 7 Phase 2 VPP and Quality Chemicals Industries. The confirmed shipment dates places the country in a situation of vulnerability if no alternative source of the stocks is mobilised before July 2012.

The on-going discussion on how to improve availability of these products to the PNFP sector is almost complete. The rationalization team under MoH will be completing the exercise by end of June 2012. PEPFAR continues to provide temporary support to the PNFPs/PFPs and limited amount of facility level buffering.

TDF/3TC is at high risk of stocking out as the consumption trends continue to rise despite a halt on transition to Option B+ for PMTCT. There is need to work out efficient mechanisms to ensure the stocks are shared equitably over the period before stock levels become stable. To mitigate the stock situation, Government has requested for stock gap quantities from PEPFAR.

Medium

Stock levels of all adult first line formulations are stable with risk of continuity of supply predicted around June 2012. NVP levels are below minimum level. There is need to complete the preparation of an harmonized supply plan for the ARV medicines



B) - Second Line

UNITAID donation through CHAI is expected to meet all the country requirements until June 2012. The stock levels for all adult second line ARVs except LPV/r are within the recommended max-min range for central level. However, much of the stock is placed at NMS, with little at JMS. There is need to expedite orders for LPV/r to avert stock outs before July 2012

High

LPV/r stock level is low. Other products are also at risk of stocking out

ARVs for Children

The stock level for almost all pediatric ARVs are above maximum level with health facilities especially those supported by Implementing Partners having a similar situation. There is need to consider redistribution of stock between NMS and JMS and to monitor and review the current pipeline and demand situation to ensure that the products do not end up piling up at NMS/JMS. A number of products are candidates for re-export if wastage is to be avoided.


The roll-out of fixed-dose pediatric formulations has steadily gained momentum but the phase-over between formulations remains to be poorly supervised. The single pills and syrups are at risk of expiring as they cannot easily be re-exported as many countries are having a similar trend.

UNITAID donation through CHAI for Adult second line ended in April 2012 while that of pediatric will continue through to December 2012. There is need to plan for continuity of the supply for the commodities currently being supplied under this arrangement

Low for stock-out

Possible expiry looming

Stocks are being distributed well between JMS and NMS. Need to place emphasis on shift within formulations and overall utilization to prevent stock piles. **Consider re-exports where possible for overstocked products**





Laboratory Commodities

Laboratory commodities still present a fluctuating situation. There is still difficulty in maintaining the minimum-maximum parameters due to challenges in both supply and demand. There is an on-going Laboratory logistics system assessment and categorization of products into kits. It is hoped over the next six months that a baseline will be established. Majority of the commodities are at risk of stocking out.

A) - HIV Test Kits and disease monitoring supplies

Consumption data of most test kits remain unrealistic and makes prediction of country needs difficult. Few facilities are ordering their real requirements as a lot of buffer stock comes from elsewhere. JMS has stocked out of the HIV test kits. The pipeline of the products remains poor in terms of predictability. Global Fund is expected to supply the kits in Round 7 Phase 2 grant.

B) - Malaria Rapid Diagnostic Test Kits


AMFm orders for the RDTs have been confirmed and are expected in June 2012. The country risks failing to absorb the AMFm grant that expires in December 2012 if orders are not well planned before end of May 2012. NMCP and pharmacy should revisit the roll-out strategy and overall supply plan for the RDTs.

C) - Other Laboratory commodities

The other laboratory commodities have remained at below minimum stock levels.

High

The stock levels remains poor. CD4 reagents have stocked out while many products remain at bare minimum.



Anti TB Medicines


NMS procurement of emergency TB medicines has managed to provide temporary relief to the stock-outs experienced in first quarter of 2012. RHZE, RHE and EH which are the key products for TB management are at below minimum stock level and there is need to reprioritise funds at NMS to provide relief until August 2012 when Global Fund stocks from Global Drug Facility (GDF) should start arriving in-country. A total of one year's stock is planned under Global Fund Single Stream Funding (SSF).

We used the consumption rate between Jan - June 2011 to determine AMCs which was before the spike in consumption which was raised by the issues to UPDF and the recent stock outs do not give reliable AMCs. GDF has not stuck to the supply plan hence all the stocks will be coming in at once in August. In addition GDF has sent quantities for all commodities that are more than what was ordered. case in point is the stock of RH pediatric which is 11 times more than what was ordered

RH Pediatric formulation is overstocked. Current stock expires in December 2013. High risk of expiry without increased uptake. Consider use in high adult and Pediatric consumption centers. Pyrazinamide has expired as it is no longer used as a single pill. As Pyrazinamide will no longer be stocked it is recommended that it be deleted from the Stock Status Report. Pyrazinamide was not ordered by the country but was part of a global redistribution effort. Isoniazid is planned under the GF SSF and will come in to support the Intermittent Preventive Treatment for HIV/TB co-infection.

Over stocked

Over stocked



RH Commodities

These items are funded by USAID, UNFPA, MoH (GoU and World Bank funding) and Global Fund Round 7 no-cost extension (for the male and female condoms). The Contraceptive Supply Plan for the country has been developed and different partners are committing to selected products.


Consumption levels of products earlier considered at risk of expiry have improved tremendously since the introduction of Uganda Health Marketing Group (UHMGM) as an alternative distribution channel. Products no longer at risk of expiry. Microlut is stocked out at NMS but available at facility level. Due to a high demand and limited storage space at NMS, consider alternate storage and distribution channels through UHMGM and JMS.

Emergency contraceptive pill and Misoprostol are still over stocked despite use of alternative supply channel from UHMGM.

Alternative channel for distribution of Contraceptives to the private sector through Uganda Health Marketing Group (UHMGM) has started working and is expected to decongest the public sector supply backlog in the next few months.

Medium

The Contraceptive Supply Plan for the country is being updated. Male and female condoms and implants have stocked out



Other Medicines for HIV Opportunistic infections

The Fluconazole tablets donated by Pfizer are available at NMS and JMS. The overall ordering system continues to need more monitoring to ensure facilities do not run out of stock.

Stock levels for Cotrimoxazole 960mg for prophylaxis in HIV patients has run extremely low and is at risk of total stock out. There is need to place orders and revisit the current framework contract. Additional supply is expected to come in-country by August 2012 through GFATM HIV Round 7 phase 1 no-cost extension procurement.

High

Products are available at central level


HSSIP Tracer Medicines and Commodities

Stock levels for the products remain low with poor pipeline information. Measles vaccine has now been included into the stock status report.

Sulphadoxine/Pyrimethamine has stocked out while the measles vaccines is at risk of stock out. ORS is well stocked while Cotrimoxazole remains at below minimum stock.

Medium

Products are available at central level



Data Sources



Data on stocks was collected from National Medical Stores, Joint Medical Stores and National TB & Leprosy Programme

ACTs and other Malaria Medicines (Max MOS: 6 , Min MOS: 4 for central level)

* Average Monthly Consumption is estimated using NMS and JMS issues data for last four months

AMC = Average Monthly Consumption; NMS = National Medical Stores; JMS = Joint Medical Stores; MOS = Months of Stock

AMCs were obtained from JMS and NMS issues data for period of December 2011 - April 2012

Description	Unit	Inventory NMS at 1st May 2012	Inventory JMS at 1st May 2012	Total Inventory (Central Level)	Estimated Average Monthly Consumption	Estimated Months of Stock (Central Level)	Quantity on Order	Months of Stock on Order	Expected Delivery Date	Comments
1 Artemether-Lumefantrine 20/120mg tab (Green), 24 pack*	30 Strips	16	12,475	12,491	37,649	0.3	74,400	2.0	Mar-2012	The product has stocked out at NMS while JMS stock level is stable. Quality Chemicals Delivery for two months supply was expected in March 2012. Stocked out as NMS supplies the majority of health facilities in the country
2 Artemether-Lumefantrine 20/120mg tab (Brown), 18 pack*	30 Strips	13,969	10,825	24,794	16,321	1.5				No confirmed deliveries in the pipeline. Global Fund Round 10 malaria grant has also been signed and there is need to place orders with Voluntary Pooled Procurement (VPP). High risk of stock out
3 Artemether-Lumefantrine 20/120mg tab (Blue), 12 pack*	30 Strips	23	8,160	8,183	15,908	0.5				No confirmed delivery in the pipeline. Similar approach to the 18 pack required. High risk of stock out
4 Artemether-Lumefantrine 20/120mg tab (Yellow), 6 pack*	30 Strips	154,037	39,043	193,080	47,923	4.0				Product stock level is at minimum level. No firm orders in place despite huge commitments under AMFm and Global Fund Round 10 Grant. There is need to urgently place an order to avert possible stock out. Risk of Stock out
5 Artesunate Injection 60mg/ml with Sodium bicarbonate diluents	Vial	-	-	-						Artesunate injection is not yet stocked at NMS and JMS. Policy change from Quinine to Artesunate for severe malaria has been passed by the MoH. A clear transition plan is required to ensure stability in stock situation. The MoH Pharmacy is preparing a transition plan to guide NMS and JMS on best approach.
6 Quinine HCl injection, 600mg/2ml ampoule	100	895	1	896	2,245	0.4				The stock level of Quinine remains at below minimum level. Currently NMS is continuously calling off stocks from the framework contract. The policy change to use of Artesunate in favour of Quinine injection has been ratified. NMS to plan on cautiously call off stocks to prevent any stock pile
8 Sulphadoxine-Pyrimethamine 500/25mg tab*	1000 tab	638	-	638	2,206	0.3	4,500	2	Mar-12	Product is out of stock and there is huge demand for it for the intermittent presumptive treatment of malaria in pregnancy. NMS needs to expedite the call-off of the stock from the framework contract. Stocked out

Anti TB Medicines (Max MOS: 12, Min MOS: 6 for central level) Central Stores

* Average Monthly Consumption is estimated using consumption data from the facilities.

AMC = Average Monthly Consumption; NTLTP = National TB & Leprosy Program

705.072

Description	Unit	Inventory at NMS (as at May 25, 2012)	Inventory at NTLTP (as at May 25, 2012)	Est. stocks at Facility level (as of May 25, 2012)	Estimated Average Monthly Consumption	Estimated Months of Stock (Total system)	Quantity on Order	Months of Stock on Order	Expected Delivery Date	Comments
1 RHZE tablet 75/150/275/400/ mg	Blisters	186,000	-		24,164	7.70	891,072	36.9	August and September 2012	NMS is in the process of having the whole country distributed with this product. The reporting for commodities is still extremely low across the country. The NTLTP is circulating a status communication from the M.o.H to increase reporting for anti TB medicines. Global Fund medicines are expected in September 2012 basing on the shipment plans provided.
2 EH two-week blister strip 400/150 mg	Blisters	172,896	-		26,780	6.46	827,424	30.9	August and September 2012	NMS is in the process of having the whole country distributed with this product. The reporting for commodities is still extremely low across the country. The NTLTP is circulating a status communication from the M.o.H to increase reporting for anti TB medicines. Global Fund medicines are expected in September 2012 basing on the shipment plans provided.
3 Isoniazid 300mg tablet	Blisters	-	-		383	0.00				The consumption of the product has increased with the rapid expansion of it's use in the Isoniazid prophylaxis for HIV/TB co-infection program. An order is planned as part of the Global Fund SSF. All stocks are with partners
4 Pyrazinamide tablet 400 mg	Blisters	-	-	-						No further order need to be placed. this product should be deleted from stock status report
5 RH (Adult) tablet	Blisters	-	-							No stock available at central level but facilities and districts are having borderline stock levels. The uptake of this product went up with the stock-out of EH.
6 RH (Pediatric) tablet	Blisters	-	73,512		1,644	44.72	878,808	534.6	July and August 2012	Consumption level has not improved since last stock status report. The highest proportion of the stocks are at central level with a slow uptake still being experienced. NTLTP is currently working with the zonal offices to verify pediatric cases in respective district to ensure the children receive their much needed supplies. Stocks expire in December 2013. High risk of expiry without increased uptake. Consider use in high Pediatric consumption centers.
7 RHE (75/150/275 mg)	Blisters	-	-		2,318		143,616	62.0	August and September 2012	Central level has stocked out although the districts still have some stocks. NMS has placed an emergency procurement for this product and stocks are expected by July 2012. Stocked out
8 RHZ (Pediatric) tablet 60/30/75 mg	Blisters	-	18,642		2,139	8.72	59,151	27.7	July and August 2012	Stock levels are still adequate at central level. Low risk of expiry

Streptomycin vial 1g	Vial	139,198				18,006	7.73	269,300	15.0	August and Spetember 2012	Central lecel has adequate stocks for this product. Low risk of expiry
MDR MEDICATIONS											
Description	Unit	Inventory at NMS (as at March 1, 2012)	Inventory at NTLP (as at May 1, 2012)	Est. stocks at Facility level (as of May 1, 2012)	Estimated Average Monthly Consumption	Estimated Months of Stock (Total system)	Quantity on Order	Months of Stock on Order	Expected Delivery Date	Comments	
PYRAZINAMIDE 500MG TABLETS	Tablets	249,600								Items are for a new MDR programme in the NTLP, the quantities are earmarked to treat 100 patients	
CAPREOMYCIN 1G VIALS	Vials	2,100								Items are for a new MDR programme in the NTLP, the quantities are earmarked to treat 100 patients	
CYCLOSERINE 250MG TABLETS	Tablets	187,200								Items are for a new MDR programme in the NTLP, the quantities are earmarked to treat 100 patients	
ETHIONAMIDE 250MG TABLETS	Tablets	187,200								Items are for a new MDR programme in the NTLP, the quantities are earmarked to treat 100 patients	
KANAMYCIN 1G VIALS	Vials	6,000								Items are for a new MDR programme in the NTLP, the quantities are earmarked to treat 100 patients	
LEVOFLOXACIN 250MG TABLETS	Tablets	224,600								Items are for a new MDR programme in the NTLP, the quantities are earmarked to treat 100 patients	
MOXIFLOXACIN 400MG TABLETS	Tablets	6,200								Items are for a new MDR programme in the NTLP, the quantities are earmarked to treat 100 patients	
PASER 4 GM SACHETS	Sachets	24,960								Items are for a new MDR programme in the NTLP, the quantities are earmarked to treat 100 patients	

Reproductive Health Items (Max MOS: 12 , Min MOS :6 for central level)

Note

* Average Monthly Consumption is estimated using adjustments to the Contraceptive Procurement Table (CPT) 2011
 ** Average Monthly Consumption is estimated using NMS issues data up to 31/March/2012

AMC = Average Monthly Consumption; NMS = National Medical Stores

Description	Unit	Inventory NMS at 1st May 2012	Inventory at UHMG May 1, 2012	Estimated Average Monthly Consumption	Estimated Months of Stock (Central Level)	Quantity on Order	Months of Stock on Order	Expected Delivery Date	Comments
1 Depo-Provera (Medroxyprogesterone Acetate 150mg/ml INJ)*	Vial	198,300	42,260	134,095	1.8	2,277,600	17.0	Jul-2012	The stock level of the product is still below minimum. The product has been prioritised for GoU funding under Vote 116. The alternative distribution channel through the UHMG has greatly contributed to availability and improved utilisation at health facility and community levels. There is need to expedite the order for this product to avoid a stock out. No risk of stock out
2 Implants (Implanon & Jadelle)*	Piece	37,509	56,128	6,000	15.6	71,064	11.8	Jul-2012	The stocks of implants are still outside the expected stock parameters. Efforts of alternative distribution channel is now beginning to be evident and the previous risk of expiry has greatly reduced. 11 months of stock expected in July 2012. 56,000 from UNFPA and 15,000 from GOU vote 116. There is need to stagger pipeline deliveries best on consumption trends. Low risk of stock out.
3 IUD - Copper Containing Device TCU380A**	Piece	1,983	14,496	1,900	8.7	10,000	5.3	Aug-2012	The actual consumption of IUD Copper T is below the projected consumption from the CPT. Stocks in the pipeline expected in August 2012. Alternative channel of distribution through Uganda Health Marketing Group (UHMG) has improved utilisation but there is still need to monitor the user level consumptions. No risk of stock-out
4 Combined Oral Contraceptives (Microgynon)**	Cycles	410,163	107,297	35,000	14.8	210,000	6.0	Jun-2012	The commodity has stocked out of NMS but available in UHMG. The actual consumption of Microgynon through the public sector outlet remains low compared to the projected CPT consumption with evidence of accumulation at facility level. UHMG has improved utilisation but reporting from user level is still low. USAID supplying 210,000 cycles in June. Low risk of stock-out.
5 Progestin-only oral contraceptives (Microlut)(Norgestrel 0.075mg)**	Cycle	-	-	3,500	-	-	-	-	Product stocked out but still available at health facility level. Review of current needs and allocation of orders expected from the World Bank UHSSP support. Stocked-out
6 Male Condom (52MM with and without Logo)*	Piece	8,347,248	4,000,000	4,878,008	2.5	54,000,000	11.1	Jun-2012	Global Fund and USAID bringing stock in June, August and October 2012. There is need to consider use of social marketing as an alternative distribution channel. Current bottleneck to availability is the testing capacity at NDA that is too slow to meet the country demands. Consider engaging NDA to improve turn-around time. Stock still below minimum.
7 Manual Vacuum Aspiration (MVA) Double Valve**	Kit	2	-	126	0.0	-	-	-	NMS issued out most of the available stock in September 2011 after receiving an allocation list from the Reproductive health division. No stock on order. NMS needs to expedite the procurement process
Mama Kit**	Kit	20,449	-	18,093	1.1	25,000	1.4	May-2012	The demand for mama kit is currently above the supply capacity with a total of 72,332 kits have been issued from January to 30/April/2012. 25,000 kits are coming each month from the framework contract that covers at least two years. It is recommended that NMS supplies as demanded and monitor consumption to establish realistic AMC. Stable stock situation
8 Female Condom**	1000	-	68,000	-	-	500,000	-	Jun-2012	Stocked out at NMS but available through UHMG for private sector channel. Global Fund is supplying 500,000 condoms in May 2012 and will be available for distribution in June 2012. UHMG should monitor stock and establish AMC for this product.
9 Levonorgestrel 750 mcg Tab (Emergency Contraceptive)**	Pack	617,907	2,001	16,794	36.9	-	-	-	Although there is a high demand for ECP in the private sector. Uptake continues to be extremely low in the public with a possible risk of expiry. The MoH is distributing this product through alternative access channels using UHMG. High risk of expiry
10 Misoprostol 200mcg Tabs**	1 Tablet	1,832,280	52	72,800	25.2	-	-	-	Very low uptake. Procurement pipeline under Vote 116 has been cancelled and funds to be re-allocated to cater for other RH commodities under same Vote. High risk of expiry.

ARV, Fluconazole, HIV test kits (Max MOS: 6 , Min MOS :4 for central level)

* Average Monthly Consumption is estimated using health facility reports

** Average Monthly Consumption is estimated using NMS and JMS issues data

*** Average Monthly Consumption is estimated using scale-up plan

AMC = Average Monthly Consumption; NMS = National Medical Stores; JMS = Joint Medical Stores

Description	Unit	Inventory NMS at 1st May 2012	Inventory JMS at 1st May 2012	Total Inventory (Central Level)	Estimated Average Monthly Consumption	Estimated Months of Stock (Total System)	Quantity on Order	Months of Stock on Order	Expected Delivery Date	Comments
A Adult Formulations										
Lamivudine 150mg + Zidovudine 300mg + Nevirapine 200mg***	60	344,617	0	344,617	90,974	3.8	266,000	2.9	Jun-2012	Stock levels are below minimum. Of the stock in the pipeline, 110,000 packs are expected in May 2012 from existing NMS procurement contract with Quality Chemicals. The balance will come in June 2012. However, JMS is stocked out of the product and the earliest expected delivery from Global Fund to JMS will be in September 2012. Borderline stock at NMS while JMS is stocked out
Lamivudine 150mg + Zidovudine 300 Mg Tab**	60	109,137	0	109,137	55,143	2.0	222,491	4.0	Jun-2012	Stock levels have fallen below minimum due to delays in execution of planned procurements. Of the stock in the pipeline, 75,000 packs are expected in May 2012 from existing NMS procurement contract with Quality Chemicals. The balance will come in June 2012. Global Fund stocks expected in July 2012. JMS is stocked out. Stocked out
Nevirapine 200mg Tab**	60	75,066	0	75,066	42,100	1.8	123,077	2.9	Jun-2012	Stock levels have fallen below minimum due to delays in execution planned procurements. The stock in the pipeline is expected in June 2012 from Quality Chemicals to NMS and Global Fund. Consider stock movement from other central medical stores and supply systems. JMS is stocked out. Stocked out
TDF/3TC 300/300mg Tabs**	30	125,077	37,982	163,059	49,955	3.3	113,482	2.3	Jun-2012	Consumption for product which had previously shot up is at peak level due to a halt in implementation of the policy change. UNITAID donation arrived but is not sufficient to cover country needs. NMS at risk of stocking out by June 2012, however, the stock in the pipeline is expected in June 2012 from Quality Chemicals to NMS. Consider stock movement from other central medical stores and supply systems. Extremely high risk of stock-out
Efavirenz 600mg Tab**	30	36,671	0	36,671	40,631	0.9	184,265	4.5	Aug-2012	Stock level is near zero with next expected delivery too late to mitigate possible spell of stock out. Consider stock movement from other central medical stores and supply systems. Stocked out
Lopinavir 200mg+Ritonavir 50mg Tab (LPV/r)**	120	7,557	5,927	13,484	4,708	2.9	21,467	4.6	Jul-2012	Country has stocked out of this product however, of the quantities in the pipeline, 14,801 packs are expected to be delivered through UNITAID donation in July 2012. This will be the last UNITAID donation for this product. Global Fund stocks are expected in September 2012. Stocked out.
Abacavir Sulfate Tablets 300mg**	60	1,620	476	2,096	704	3.0				Pipeline Stocks expected to be in the system but not available for use at time compiling the report
Didanosine 250mg Tab**	30	3,552	771	4,323	497	8.7				Supplies previously came from UNITAID/CHAI donation. UNITAID/CHAI donation for this product has ended, however, use of this product is no longer preferred as per the treatment guidelines. No risk of stock-out
Didanosine 400mg Tab**	30	1,717	443	2,160	641	3.4				Supplies previously came from UNITAID/CHAI donation. UNITAID/CHAI donation for this product ended, however, use of this product is no longer preferred as per the treatment guidelines. No risk of stock-out
Zidovudine 300mg Tab**	60	108,578	33,650	142,228	12,903	11.0				Global Fund procurement was cancelled. Following NAC recommendation to maintain patients on Option A for PMTCT unit country has sufficient funds, this product will continue to be used for PMTCT. No risk of stock-out

Description	Unit	Inventory NMS at 1st May 2012	Inventory JMS at 1st May 2012	Total Inventory (Central Level)	Estimated Average Monthly Consumption	Estimated Months of Stock (Total System)	Quantity on Order	Months of Stock on Order	Expected Delivery Date	Comments
Atazanavir 300 mg Capsules	30	9,936	1,998	11,934	0					No more order expected for this product. The fixed dose combination has been prioritized. Existing stock to be used in combination with ritonavir for new patients second line patients. No risk of stock-out
Atazanavir 300mg+Ritonavir 100 mg Tabs	30	0	0	0	0					New preferred PI for use in 2nd line in adult patients. Consumption figures yet to be fully established.
Ritonavir 100 mg Tabs	60	2,801	500	3,301	0					No more order expected for this product. The fixed dose combination has been prioritized. Existing stock to be used in combination with ritonavir for new patients second line patients. High risk of expiry

Description	Unit	Inventory NMS at 1st May 2012	Inventory JMS at 1st May 2012	Total Inventory (Central Level)	Estimated Average Monthly Consumption	Estimated Months of Stock (Total System)	Quantity on Order	Months of Stock on Order	Expected Delivery Date	Comments
B Pediatric Formulations										
Abacavir Sulfate Oral Solution 240ml 20mg/ml**	240ml	1,305	0	1,305	176	7.4				Being phased out with the introduction of ABC 60mg. There is need to monitor consumption situation. Prioritize use to avoid expiry
Abacavir 60mg (dispersible)	60	500	200	700	0		500		Jun-2012	New dispersible formulation to replace Abacavir oral solution. Consumption figures yet to be fully established.
Abacavir/Lamivudine 60/30mg tab**	60	14,777	1,998	16,775	1,102	15.2	7,331	6.7	Jun-2012	Stable stock situation with good pipeline. Planned scale-up is expected to increase consumption of the product. High risk of expiry. Consider cancelling quantity on order
Efavirenz 200mg Cap**	90	19,587	22,893	42,480	2,732	15.5				There is planned scale-up on this product. Consumption is expected to rise. Currently over-stocked.
Lamivudine 30mg+Zidovudine 60mg Tablets**	60	15,554	5,536	21,090	1,926	11.0				The pipeline information remains unclear. The scale-up plan has led to increase in overall consumption for the product. No risk of stock out
Lamivudine 30mg+Zidovudine 60mg+Nevirapine 50mg**	60	43,091	13,074	56,165	5,403	10.4				Stable stock situation. No risk of stock out
Lamivudine 60mg+Stavudine 12mg+Nevirapine 100mg**	60	4,038	4,145	8,183	784	10.4				Product expected to be phased out with all d4T FDCs being harmonised around d4T/3TC 6/30mg formulation.
Lamivudine 30mg + Stavudine 6mg + Nevirapine 50 mg Tab***	60	24,660	7,251	31,911	2,845	11.2	9,922	3.5		Product expected to take up all patients on other d4T formulations. Consumption is based on scale-up plan.
Lamivudine 30mg + Stavudine 6mg Tab	60	10,720	0	10,720	396	27.1	1,626	4.1	May-2012	Product expected to take up all patients on other d4T formulations. Consumption is based on scale-up plan. Stock is way above maximum. Consider stock movement from NMS to JMS and re-exporting. Current stocks expire April/Oct 2013. High risk of expiry
Lamivudine Oral Solution 50mg/ml**	240ml	1,962	0	1,962	216	9.1				Product is being phased out. Prioritize use to avoid expiry.
Lopinavir 80mg + Ritonavir 20mg**	5X60ml	0	2,170	2,170	90	24.1				Stock is way above maximum. Consider part of the stock moved from JMS to NMS. High risk of expiry.
Lopinavir+Ritonavir 100mg/25mg**	60	591	240	831	120	6.9				Stable stock situation.
Nevirapine 50mg/5ml Susp**	240ml	599	3,562	4,161	1,616	2.6				Pack size being phased out in favour of dispersible tablets
Nevirapine 50mg/5ml Susp**	100ml	187,328	20,694	208,022	14,418	14.4				Pack size being phased out in favour of dispersible tablets. Promote use of the product to avoid expiry.
Nevirapine 50mg	30	6,000	4,000	10,000	0	N/A				New product that will replace the NVP oral suspensions. Not being used at the moment. Consumption is based on scale-up plan

C Other Medicines for Opportunistic infections										
Description	Unit	Inventory NMS at 1st May 2012	Inventory JMS at 1st May 2012	Total Inventory (Central Level)	Estimated Average Monthly Consumption	Estimated Months of Stock (Total System)	Quantity on Order	Months of Stock on Order	Expected Delivery Date	Comments
Fluconazole (Diflucan)**	28	47,625	0	47,625	4,938	9.6				Supply received from the Diflucan Donation Program. Facilities have not been ordering for adequate quantities. Low risk of stock out
Fluconazole 2mg/ml I.V. Infusion 100ml (Diflucan)**	100ml	2,981	0	2,981	228	13.1				Supply received from the Diflucan Donation Program. Facilities have not been ordering for adequate quantities. Low risk of stock out
Fluconazole 50mg/5ml oral suspension (Diflucan)**	35ml	2,712	0	2,712	334	8.1				Supply received from the Diflucan Donation Program. Facilities have not been ordering for adequate quantities. Low risk of stock out
Cotrimoxazole 960mg Tab**	1000	12	1	13	16,404	0.0	87,180	2.7	Jul-2012	Of the stock in the pipeline 46,154 should arrive in May from Global Fund, this stock is very low with NMS and JMS already stocked out. There is need to review the supply side to ensure continuity. Stocked-out

Laboratory Commodities - Reagents, Kits and Consumables (Max MOS: 10 , Min MOS :5 for central level)

Note

AMC = Average Monthly Consumption; NMS = National Medical Stores; JMS = Joint Medical Store; CPHL = Central Public Health Laboratories

Description	Unit	Inventory NMS at Mar 1, 2012	Inventory JMS (Credit Line) at Mar 1, 2012	Total Inventory (Central Level)	Estimated Average Monthly Consumption	Estimated Months of Stock (Central Level)	Quantity on Order	Months of Stock on Order	Expected Delivery Date	Comments
1 Carbo-fuschin solution	1000ml	-	-	-	216					The stock parameters for this product is yet to be fully established. The NTLP and the NMS are working on modalities to ensure sustained supply of quality reagents. Recommended that the supply pipeline is reviewed and stabilised to ensure effective TB diagnosis
2 Methylene blue 0.5% solution	100ml	67	-	67	298	0.2				Current stock levels are below recommended. No clear pipeline information exist. It was not possible to ascertain the stock situation at JMS. There is need to review the demand and supply situation.
3 Field Stain A solution	1000ml	2,216	-	2,216	401	5.5				Stock level is stable and within the min-max parameters. The product consumption went up from previous reporting period
Gram Iodine solution 1000ml	Bottle	-	-	-	18					The product has stocked out with no planned delivery confirmed. NMS has framework contracts for supply of this product. There is need to place an order to immediately address the stock situation.
4 Malaria Rapid diagnostic kits	Kit	-	1,326,450	1,326,450			7,800,000		Jun-2012	The product has been stocked out for last seven months. JMS received consignment of 53,000 packs of 25 tests in February from PMI. An additional 7.8 million test kits are expected from AMFm grant. The realistic demand situation for the country is yet to be ascertained. The MoH (NMCP) needs to provide stronger guidance on roll-out of the product.
5 RPR Kit 100 tests pack	Kit	1,875	-	1,875	684	2.7				Stock level is below minimum recommended and consumption is extremely low. There is need to review the ordering and reporting for the product following conclusion of the review of the laboratory supply lists. There is a risk of stock out
6 Unigold rapid test kit	Kit	78,740	-	78,740	26,800	2.9				Stock level is below recommended level with constantly changing demand situation. The projected consumption is much higher than current level being reported at the central medical stores. CPHL should consider reviewing the current ordering and supply chain mechanisms for the HIV/AIDS Laboratory commodities. There are planned shipments in the pipeline under Global Fund but exact quantities remain unclear. High risk of stock out
7 Stat-pack rapid test kit	Kit	500,070	10,290	510,360	118,125	4.3				Stock level is stable while demand remain highly fluctuating. The projected consumption is much higher than current level. CPHL should consider reviewing the current ordering and supply chain mechanisms for the HIV/AIDS Laboratory commodities. Stocks are expected from Global Fund HIV Round 7 grant but quantities are yet to be confirmed. Low risk of stock out
8 HIV Determine Rapid Test Kit	Kit	20,500	-	20,500	586,250	0.0				Stock level is below minimum recommended. The demand for the product remains fluctuating making the projected consumption is much higher than current level. CPHL should consider reviewing the current ordering and supply chain mechanisms for the HIV/AIDS Laboratory commodities. Stocks are expected from Global Fund HIV Round 7 Phase 2 grant. Stocked out.
9 Facs count reagent kit	Kit	4,050	-	4,050	9,450	0.4				The product went from being over-stocked to stocking out completely. NMS has been unable to confirm the orders due to the then review of the laboratory supply list and overall quantification exercise. The new machines have begun working. CPHL and ACP need to harmonise the HIV/AIDS Laboratory Commodities supply chain to improve ordering. Stocked out
10 Parthec reagent kit	Kit	45	-	45	39	1.2				NMS and JMS were both stocked out and this product is considered alternative to Facs count reagent kit. Stocked out
11 HB reagent	Pack	-	-	-	104					Stock level is below minimum recommended and consumption is extremely low. There is need to review the ordering and reporting for the product. This is first time the product is being tracked in the bi-monthly reports. Stocked out

Ministry of Health Tracer Medicines (Max MOS: 6 Min MOS: 4 for central level)

Note

* Average Monthly Consumption is estimated using NMS issues data

AMC = Average Monthly Consumption; NMS = National Medical Stores

Description	Unit	Stock on Hand March 1, 2012	Estimated Average Monthly Consumption	Estimated Months of Stock (Central Level)	Quantity on Order	Months of Stock on Order	Expected Delivery Date	Comments
1 Depo-Provera (Medroxyprogesterone Acetate 150mg/ml INJ)*	Vial	240,560	134,095	1.8	2,277,600	17	41,091	The stock level of the product is still below minimum. The product has been prioritised for GoJ funding under Vote 116. The alternative distribution channel through the UHMG has greatly contributed to availability and improved utilisation at health facility and community levels. There is need to expedite the order for this product to avoid a stock out. No risk of stock out
2 Sulphadoxine-Pyrimethamine 500/25mg tab*	1000 tab	638	2,206	0.3	4,500	2	40,969	See comments under malaria commodities
3 Artemether-Lumefantrine 20/120mg tab (Yellow), 6 pack*	30 Strips	193080	47923	4.0				See comments under malaria commodities
4 Cotrimoxazole 480mg	1000 tab	22,711	9,000	2.5				Stock levels below minimum. No pipeline information. High risk of stock out
5 Oral Rehydration Salts for 1 Litre	25	84,864	15,943	5.3				Stable stock situation. Low risk of stock-out
6 Measles Vaccine	Vial	294,560	203,106	1.5				Measles vaccine stock level is below minimum of two months. There are planned procurements that have to be confirmed. High risk of stock out.